Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the clinical efficacy and safety of electroacupuncture (EA) in treating Generalized Anxiety Disorder (GAD). Participants will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group. All participants will continue their routine medication (Paroxetine). The primary goal is to observe the reduction in anxiety symptoms using the Hamilton Anxiety Scale (HAMA). Additionally, the study will use functional MRI (fMRI) and Magnetic Resonance Spectroscopy (MRS) to explore the brain mechanisms through which EA helps alleviate anxiety.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Electroacupuncture (EA) Group | Experimental | Paroxetine Hydrochloride Tablets + Electroacupuncture |
|
| Sham Electroacupuncture (SEA) Group | Sham Comparator | Paroxetine Hydrochloride Tablets + Sham Electroacupuncture |
|
| Waiting-list (WL) Group | Active Comparator | Paroxetine Hydrochloride Tablets + Delayed EA Treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Electroacupuncture (EA) | Procedure | Electroacupuncture (EA) is performed at acupoints including GV20 (Baihui), EX-HN1 (Sishencong), GV29 (Shenting), EX-HN16 (Anmian, bilateral), HT7 (Shenmen, bilateral), PC6 (Neiguan, bilateral), CV6 (Qihai), CV4 (Guanyuan), ST36 (Zusanli, bilateral), SP6 (Sanyinjiao, bilateral), and LR3 (Taichong, bilateral). Sterile disposable needles (φ0.18×25mm or φ0.25×40mm) are used. Electric stimulation (continuous wave, 100Hz) is applied to specific point pairs (e.g., left Sishencong + anterior Sishencong) for 30 minutes. The current intensity is adjusted to the patient's maximum tolerance. Treatment is administered 3 times per week for 4 weeks (12 sessions total). |
| Measure | Description | Time Frame |
|---|---|---|
| Effective rate of HAMA score reduction at Week 4 | The percentage of participants who achieved a HAMA score reduction rate of ≥50% from baseline. HAMA scores are evaluated to categorize outcomes as recovered, markedly effective, effective, or ineffective. | Week 4 (at the end of treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in Hamilton Anxiety Scale (HAMA) Scores | HAMA is used to assess the severity of anxiety symptoms. It contains 14 items, including somatic and psychic anxiety. Total scores range from 0 to 56, where higher scores indicate more severe anxiety | Baseline, Week 2, Week 4, and Week 8 |
| Change from Baseline in Social Disability Screening Schedule (SDSS) Scores |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lishu Gao | Contact | +86 13858015836 | rodelo@sina.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000098647 | Generalized Anxiety Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D015671 | Electroacupuncture |
| ID | Term |
|---|---|
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
| D015670 | Acupuncture Therapy |
| D000529 | Complementary Therapies |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Sham Electroacupuncture (SEA) | Procedure | Sham electroacupuncture (SEA) is performed by inserting needles into non-acupoints located 5-10 mm away from the real points used in the EA group. Shallow needling (depth of 1-2 mm) is applied. A sham EA device with a disconnected electrode lead is used; although the screen displays parameters identical to the EA group, there is no actual current output. The duration, frequency, and total number of sessions are identical to the EA group (3 times/week for 4 weeks). |
|
| Routine Medication | Drug | All groups receive Paroxetine Hydrochloride Tablets (20 mg/tablet). The initial dose is 20 mg once daily, taken orally. The daily dose may be increased in increments of 10 mg based on the patient's condition, with a minimum interval of 1 week between adjustments. The maximum daily dose is 50 mg. |
|
SDSS is used to evaluate the daily functioning of patients. It consists of 10 items, with each item scored from 0 to 2. Higher total scores reflect a higher degree of social disability. |
| Baseline, Week 2, Week 4, and Week 8 |
| Frequency of Participants with Changes in Paroxetine Dosage | The study will record whether the daily dose of Paroxetine increased, remained unchanged, or decreased compared to the baseline. | Week 2, Week 4, and Week 8 |
| Treatment Emergent Symptom Scale (TESS) Scores | TESS is used to evaluate adverse reactions to psychiatric medications, covering symptom severity, relationship with the drug, and measures taken. | Week 2, Week 4, and Week 8 |
| Changes in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF) | Twenty right-handed subjects will be randomly sampled from each group for the neuroimaging mechanism study. Resting-state functional MRI (fMRI) will be used to analyze brain activity changes. FC describes the synchronization between different brain regions; ReHo and ALFF describe the local homogeneity and intensity of brain activity. Resting-state functional MRI (fMRI) will be used to analyze brain activity changes. FC describes the synchronization between different brain regions; ReHo and ALFF describe the local homogeneity and intensity of brain activity. | Baseline and Week 4 |
| Changes in Brain Metabolite Concentrations via Magnetic Resonance Spectroscopy (MRS) | Twenty right-handed subjects will be randomly sampled from each group for the neuroimaging mechanism study. 3D 1H-MRS will be used to measure the absolute concentrations of neurotransmitters in ROI (amygdala, hypothalamus, etc.), e.g. 5-HT, NE, DA, GABA, and CRF | Baseline and Week 4 |
| D004599 |
| Electric Stimulation Therapy |
| D026741 | Physical Therapy Modalities |
| D012046 | Rehabilitation |
| D004561 | Transcutaneous Electric Nerve Stimulation |
| D000698 | Analgesia |
| D000760 | Anesthesia and Analgesia |
| D000758 | Anesthesia |